Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality worldwide, with rising clinical and economic burden as incidence increases. There are a multitude of evolving treatment options, including locoregional therapies which can be used alone, in combination with each other, or in combination with systemic therapy. These treatment options have shown to be effective in achieving remission, controlling tumor progression, improving disease free and overall survival in patients who cannot undergo resection and providing a bridge to transplant by debulking tumor burden to downstage patients. Following locoregional therapy (LRT), it is crucial to provide treatment response assessment to guide management and liver transplant candidacy. Therefore, Liver Imaging Reporting and Data Systems (LI-RADS) Treatment Response Algorithm (TRA) was created to provide a standardized assessment of HCC following LRT. LI-RADS TRA provides a step by step approach to evaluate each lesion independently for accurate tumor assessment. In this review, we provide an overview of different locoregional therapies for HCC, describe the expected post treatment imaging appearance following treatment, and review the LI-RADS TRA with guidance for its application in clinical practice. Unique to other publications, we will also review emerging literature supporting the use of LI-RADS for assessment of HCC treatment response after LRT.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: not found
          • Article: not found

          Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

            The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue. The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis. Applying these guidelines, there was an association between response rate and outcome prediction. More recently, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was proposed as a method for measuring treatment response based on tumor shrinkage, which is a valuable measure of antitumor activity of cytotoxic drugs. This method was initially adopted by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for drug approval. However, anatomic tumor response metrics can be misleading when applied to molecular-targeted therapies or locoregional therapies in HCC. In 2008, a group of experts convened by the American Association for the Study of Liver Diseases (AASLD) developed a set of guidelines aimed at providing a common framework for the design of clinical trials in HCC and adapted the concept of viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced radiologic imaging techniques-to formally amend RECIST. These amendments conformed the AASLD-JNCI (Journal of the National Cancer Institute) guidelines and are summarized and clarified in the current article. They are referred to herein as the modified RECIST assessment (mRECIST). Further studies are needed to confirm the accuracy of this measurement compared with conventional gold standards such as pathologic studies of explanted livers.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

                Bookmark

                Author and article information

                Contributors
                Journal
                World J Hepatol
                WJH
                World Journal of Hepatology
                Baishideng Publishing Group Inc
                1948-5182
                27 October 2020
                27 October 2020
                : 12
                : 10
                : 738-753
                Affiliations
                Department of Radiology, University of Michigan, Ann Arbor, MI 48019, United States. aanum@ 123456med.umich.edu
                Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
                Abdominal Imaging and Interventional Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, United States
                Department of Radiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, United States
                Department of Radiology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States
                Department of Interventional Radiology, OHSU and Tanta University, Egypt, Portland, OR 97239, United States
                Department of Radiology, Weill Cornell Medicine, New York, NY 10065, United States
                Department of Radiology, Duke University Medical Center, Duke University, Durham, NC 27710, United States
                Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT 06520, United States
                School of Medicine, 1500 East Medical Center Drive, University of Michigan, Ann Arbor, MI 48109, United States
                Author notes

                Author contributions: Aslam A analyzed the data and wrote the manuscript; Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Charalel RA, Kim CY, and Madoff DC made critical revisions related to important intellectual content of the manuscript; Mendiratta-Lala M analyzed the literature, wrote the manuscript and made critical revisions related to important intellectual content of the manuscript; and all authors have read and approve the final manuscript.

                Corresponding author: Anum Aslam, MD, Assistant Professor, Department of Radiology, University of Michigan, 1500 E. Medical Center Dr, Ann Arbor, MI 48019, United States. aanum@ 123456med.umich.edu

                Article
                jWJH.v12.i10.pg738
                10.4254/wjh.v12.i10.738
                7643220
                33200013
                cb9f351d-2a24-44d4-8d69-6f249d1c4216
                ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

                This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

                History
                : 28 June 2020
                : 7 August 2020
                : 17 September 2020
                Categories
                Minireviews

                hepatocellular carcinoma,liver imaging reporting and data systems treatment response algorithm,locoregional therapy,liver imaging reporting and data systems treatment response equivocal,arterial phase hyper enhancement,stereotactic body radiotherapy

                Comments

                Comment on this article